 | Up a level |
Journal Article
Belz, D., Rasokat, H., Poor, I and Schlaak, M. (2014). A Mycobacterium marinum Infection misinterpreted as metastatic Crohns Disease. J. Dtsch. Dermatol. Ges., 12 (12). S. E15 - 2. HOBOKEN: WILEY-BLACKWELL. ISSN 1610-0387
Belz, D., Tantcheva-Poor, I., Rasokat, H., Fabri, M. and Schlaak, M. (2016). Mycobacterium marinum infection initially diagnosed as metastatic Crohn's disease. J. Eur. Acad. Dermatol. Venereol., 30 (3). S. 514 - 516. HOBOKEN: WILEY. ISSN 1468-3083
Bruggen, M-C., Valencak, J., Stranzenbach, R., Li, N., Stadler, R., Jonak, C., Bauer, W., Porkert, S., Blaschke, A., Meiss, F., Nicolay, J. P., Wehkamp, U., Schlaak, M., Nguyen, V. A., Romani, N., Cozzio, A., Gayathri, N., Dimitriou, F., French, L. E., Dummer, R. and Guenova, E. (2020). Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study. J. Eur. Acad. Dermatol. Venereol., 34 (7). S. 1489 - 1496. HOBOKEN: WILEY. ISSN 1468-3083
Cosgarea, I, Zimmer, L., Weide, B., Gutzmer, R., Heinzerling, L., Weishaupt, C., Pfoehler, C., Gesierich, A., Herbst, R., Kaehler, K., Schlaak, M., Loquai, C., Utikal, J., Kaatz, M., Berking, C., Kreuter, A., Ulrich, J., Mohr, P., Dippel, E., Livingstone, E., Weichenthal, M., Schadendorf, D. and Ugurel, S. (2017). Interleukin-2 and Checkpoint Inhibition as a successful Therapy Sequence for metastatic Melanoma: Case Report and retrospective Analysis in 52 Patients. J. Dtsch. Dermatol. Ges., 15. S. 16 - 18. HOBOKEN: WILEY. ISSN 1610-0387
Hassel, J., Forschner, A., Bluhm, L., Heinzerling, L., Zimmer, L., Utikal, J., Kaehler, K., Schlaak, M., Loquai, C., Gutzmer, R., Kieker, F., Berking, C., Bender, A., Schneider, L., Enk, A., Garbe, C., Weichenthal, M., Schadendorf, D., Hauschild, A. and Mohr, P. (2016). Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP). J. Dtsch. Dermatol. Ges., 14. S. 9 - 10. HOBOKEN: WILEY-BLACKWELL. ISSN 1610-0387
Heindl, L. M., Koch, K. R., Schlaak, M., Mauch, C. and Cursiefen, C. (2015). Adjuvant therapy and interdisciplinary follow-up care of conjunctival melanoma. Ophthalmologe, 112 (11). S. 907 - 912. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0423
Heppt, M. V., Schlaak, M., Eigentler, T. K., Kaehler, K. C., Kiecker, F., Loquai, C., Meier, F., Tomsitz, D., Brenner, N., Niesert, A. C., Thonke, R., Hauschild, A. and Berking, C. (2017). Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients. Ann. Oncol., 28 (12). S. 3104 - 3108. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Hoerster, R., Schlaak, M., Koch, K. R., Ortmann, M., Mauch, C. and Heindl, L. M. (2017). Merkel cell carcinoma of the eyelid. An often unrecognized tumor entity. Clinical aspects and treatment strategies. Ophthalmologe, 114 (2). S. 134 - 140. NEW YORK: SPRINGER. ISSN 1433-0423
Kleffner, F., Kremer, K., Schlaak, M., Mauch, C. and Kurschat, P. (2012). Cutaneous Angiosarcoma: difficult to treat by Tumor. J. Dtsch. Dermatol. Ges., 10 (11). S. 860 - 861. HOBOKEN: WILEY-BLACKWELL. ISSN 1610-0379
Kleffner, F., Schuerholz, J., Burckhardt, S., Mauch, C. and Schlaak, M. (2014). Merkel cell carcinoma. Hautarzt, 65 (9). S. 823 - 831. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1173
Kleffner, F., Schuerholz, J., Burckhardt, S., Mauch, C. and Schlaak, M. (2015). Merkel-Cell-Carcinoma (vol 65, pg 823, 2014). Hautarzt, 66 (1). S. 52 - 53. NEW YORK: SPRINGER. ISSN 1432-1173
Kleffner-Mieth, F., Brenner, N., Tantcheva-Poor, I, Schlaak, M. and Mauch, C. (2015). Sweet-Syndrome in Ipilimumab- Therapy in Combination with Radiotherapy in a Patient with metastatic malignant Melanoma. J. Dtsch. Dermatol. Ges., 13 (12). S. 1325 - 1326. HOBOKEN: WILEY-BLACKWELL. ISSN 1610-0387
Knuever, J., Gerecht, L., Mauch, C. and Schlaak, M. (2017). Eosinophilia during immunotherapy of metastatic melanoma: A warning signal for possible side effects? J. Dtsch. Dermatol. Ges., 15. S. 70 - 72. HOBOKEN: WILEY. ISSN 1610-0387
Knuever, J., Gerecht, L., Naetlitz, M., Mauch, C. and Schlaak, M. (2017). Eosinophilia during immunotherapy of metastatic melanoma -a warning signal for possible side effects? J. Dtsch. Dermatol. Ges., 15. S. 167 - 168. HOBOKEN: WILEY. ISSN 1610-0387
Knuever, J., Gerecht, L., Naetlitz, M., Mauch, C. and Schlaak, M. (2017). Eosinophilia during immunotherapy of metastatic melanoma-A warning signal for possible side effects? Exp. Dermatol., 26 (3). S. E32 - 1. HOBOKEN: WILEY. ISSN 1600-0625
Knuever, J., Schlaak, M. and Mauch, C. (2016). Eosinophils during immunotherapies of metastatic melanoma - cause or consequence of treatment responses and side effects? J. Dtsch. Dermatol. Ges., 14. S. 32 - 33. HOBOKEN: WILEY-BLACKWELL. ISSN 1610-0387
Livingstone, E., Zaremba, A., Horn, S., Ugurel, S., Casalini, B., Schlaak, M., Hassel, J. C., Herbst, R., Utikal, J. S., Weide, B., Gutzmer, R., Meier, F., Koelsche, C., Hadaschik, E., Sucker, A., Reis, H., Merkelbach-Bruse, S., Siewert, M., Sahm, F., von Deimling, A., Cosgarea, I., Zimmer, L., Schadendorf, D., Schilling, B. and Griewank, K. G. (2020). GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma. Br. J. Dermatol., 183 (5). S. 928 - 940. HOBOKEN: WILEY. ISSN 1365-2133
Maniu, C., Kobe, C., Krieg, T., Schlaak, M., Mauch, C. and Eming, S. A. (2015). Polymyalgia rheumatica under the Therapy with Ipilimumab. J. Dtsch. Dermatol. Ges., 13 (12). S. 1322 - 1323. HOBOKEN: WILEY-BLACKWELL. ISSN 1610-0387
Mescher, M., Jeong, P., Ruebsam, M., Kranen, M., Landsberg, J., Schlaak, M., Mauch, C., Tueting, T., Niessen, C. M. and Iden, S. (2016). Non-cell autonomous suppression of melanoma by the epidermal polarity protein Par3 through control of direct keratinocyte-melanocyte interactions. J. Invest. Dermatol., 136 (9). S. S244 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1523-1747
Mescher, M., Ruebsam, M., Jeong, P., Kranen, M., Landsberg, J., Schlaak, M., Mauch, C., Niessen, C. M., Tueting, T. and Iden, S. (2015). The epidermal polarity protein Par3 acts as non-cell autonomous suppressor of malignant melanoma. J. Invest. Dermatol., 135. S. S20 - 1. NEW YORK: NATURE PUBLISHING GROUP. ISSN 1523-1747
Ochsendorf, F., Emmert, S., Hehl, N., Hornung, T., Koenig, A., Juenger, M., Kollewe, T., Loeser, C., Schlaak, M., Staender, S., Weichenthal, M. and Hamm, H. (2017). Entrustable Professional Activities (EPA): an alternative to the PJ logbook? J. Dtsch. Dermatol. Ges., 15. S. 90 - 91. HOBOKEN: WILEY. ISSN 1610-0387
Persa, O. D., Rasokat, H., Poor, I and Schlaak, M. (2014). Granulomatous Dermatitis in a 29-Year-Old Patient from Bangladesh. J. Dtsch. Dermatol. Ges., 12 (12). S. E16 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1610-0387
Pflug, N., Vitus, M., Knuever, J., Hamacher, S., Mauch, C., Schlaak, M. and Theurich, S. (2021). Treatment-specific evaluation of the modified Glasgow-Prognostic-Score in patients with advanced cutaneous melanoma. J. Eur. Acad. Dermatol. Venereol., 35 (12). S. E879 - 5. HOBOKEN: WILEY. ISSN 1468-3083
Schlaak, M., Bajah, A., von Bartenwerffer, W., Kreuzberg, N., Buettner, N., Mauch, C. and Kurschat, P. (2011). Clinical Characterization of Melanoma patients with and without activating BRAF Mutation. J. Dtsch. Dermatol. Ges., 9 (11). S. 976 - 977. MALDEN: WILEY-BLACKWELL. ISSN 1610-0379
Schlaak, M., Dummer, R., Kirkwood, J. M., Joshua, A., Milhem, M., Gastaud, L., Mauch, C., Yushak, M. L., Lockwood, S., Hayes, C. and Shoushtari, A. N. (2022). Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma. Ann. Oncol., 33 (7). S. S923 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Schlaak, M., Kurschat, P., Shimabukuro-Vornhagen, A., Scheid, C., Chemnitz, J., Stadler, R., von Bergwelt-Baildon, M. and Theurich, S. (2011). Donor lymphocyte infusions combined with systemic PUVA/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation. Transpl. Immunol., 25 (2-3). S. 163 - 167. AMSTERDAM: ELSEVIER SCIENCE BV. ISSN 0966-3274
Schlaak, M., Schmidt, P., Bangard, C., Kurschat, P., Mauch, C. and Abken, H. (2012). Current Therapeutic approaches in the Treatment of metastatic malignant Melanoma. J. Dtsch. Dermatol. Ges., 10 (11). S. 858 - 860. HOBOKEN: WILEY-BLACKWELL. ISSN 1610-0379
Schlaak, M., Schwind, S., Wetzig, T., Maschke, J., Treudler, R., Basara, N., Lange, T., Simon, J. C., Niederwieser, D. and Al-Ali, H. K. (2010). UVA (UVA-1) therapy for the treatment of acute GVHD of the skin. Bone Marrow Transplant., 45 (12). S. 1741 - 1749. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Stark-Lorenzen, P., Berking, C., Garbe, C., Gesierich, A., Huber, M. A., Pinter, A., Zimmer, L., Schlaak, M., Ulrich, J., Rech, S. and Gutzmer, R. (2015). MelaniE (Melanoma in Expert Centers)- Retrospective Data Collection for the Evaluation of the Implementation of the S3-Guideline in the oncological Clinical Practice. J. Dtsch. Dermatol. Ges., 13. S. 15 - 17. HOBOKEN: WILEY-BLACKWELL. ISSN 1610-0387
Stranzenbach, R., Dippel, E., Schlaak, M. and Stadler, R. (2018). Alternate dosing regimens of brentuximab vedotin for CD30+cutaneous T-cell lymphoma: reply from the authors. Br. J. Dermatol., 178 (1). S. 303 - 304. HOBOKEN: WILEY. ISSN 1365-2133
Stranzenbach, R., Dippel, E., Schlaak, M. and Stadler, R. (2017). Brentuximab vedotin in CD30(+) cutaneous lymphoma: How do we treat, how shall we treat? A review of the literature. Br. J. Dermatol., 177 (6). S. 1503 - 1510. HOBOKEN: WILEY. ISSN 1365-2133
Stranzenbach, R., Theurich, S. and Schlaak, M. (2017). Role of stem cell transplantation in treatment of primary cutaneous T-cell lymphoma. Hautarzt, 68 (9). S. 716 - 721. NEW YORK: SPRINGER. ISSN 1432-1173
Theurich, S., Gerecht, L., Naetlitz, J., Borggrefe, J., Zopfs, D., dos Santos, Pinto D. and Schlaak, M. (2018). Body-composition analyses in melanoma patients that undergo anti-PD-1 immunotherapy - a prospective observational pilot study. Oncol. Res. Treat., 41. S. 304 - 306. BASEL: KARGER. ISSN 2296-5262
Theurich, S., Mueller, P., Martin, K., Savic, S., Terszowski, G., Lardinois, D., Schlaak, M., Stadler, R., Kvasnicka, H. -M., Spagnoli, G., Dirnhofer, S., Speiser, D. E., von Bergwelt-Baildon, M. and Zippelius, A. (2014). Beyond cytotoxicity: Implications for immune mediated mechanisms of action of brentuximab vedotin treatment in CD30(+) lymphomas. Oncol. Res. Treat., 37. S. 31 - 32. BASEL: KARGER. ISSN 2296-5262
Theurich, S., Rothschild, S. I., Hoffmann, M., Fabri, M., Sommer, A., Marquez, M. Garcia, Thelen, M., Schill, C., Merki, R., Schmid, T., Koeberle, D., Zippelius, A., Baues, C., Mauch, C., Tigges, C., Kreuter, A., von Bergwelt-Baildon, M. and Schlaak, M. (2016). Cytotoxic local tumor treatment in combination with xystemic Ipilimumab enhances the efficacy of this immunotherapy and prolongs overall survival in patients with advanced malignant melanoma. Oncol. Res. Treat., 39. S. 8 - 9. BASEL: KARGER. ISSN 2296-5262
Theurich, S., Rothschild, S., I, Hoffmann, M., Fabri, M., Sommer, A., Garcia-Marquez, M., Thelen, M., Schill, C., Merki, R., Schmid, T., Koeberle, D., Zippelius, A., Baues, C., Mauch, C., Tigges, C., Kreuter, A., Borggrefe, J., Schlaak, M. and von Bergwelt-Baildon, M. (2016). Local treatment of tumors or metastases in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma. Oncol. Res. Treat., 39. S. 103 - 105. BASEL: KARGER. ISSN 2296-5262
Theurich, S., Schlaak, M., Steguweit, H., Heukamp, L. C., Wennhold, K., Kurschat, P., Rabenhorst, A., Hartmann, K., Shimabukuro-Vornhagen, A., Schloesser, H., Holtick, U., Hallek, M., Stadler, R. and von Bergwelt-Baildon, M. (2014). Tumor infiltrating B-cells in primary cutaneous T-cell lymphoma correlate with disease progression and might represent a novel target for immunotherapy. Exp. Dermatol., 23 (3). S. E25 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1600-0625
Theurich, S., Schlaak, M., Steguweit, H., Heukamp, L. C., Wennhold, K., Kurschat, P., Shimabukuro-Vornhagen, A., Schloesser, H., Holtick, U., Hallek, M., Stadler, R. and von Bergwelt-Baildon, M. (2014). Tumor infiltrating B-cells in primary cutaneous T-cell lymphoma correlate with disease progression and might represent a novel target for immunotherapy. Oncol. Res. Treat., 37. S. 31 - 32. BASEL: KARGER. ISSN 2296-5262
Trommer-Nestler, M., Baues, C., Ruge, M., Schlaak, M., Ruess, D., Jablonska, K., Kocher, M., Semrau, R. and Marnitz, S. (2017). Radiosurgery in melanoma patients with brain metastases under ongoing anti-PD-1 treatment. Strahlenther. Onkol., 193. S. S14 - 1. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X
Trommer-Nestler, M., Yeo, S. Y., Marnitz, S., Persigehl, T., Bunck, A., Schlaak, M., Gruell, H., Theurich, S., von Bergwelt-Baildon, M., Herter, J., Celik, E., Rosenbrock, J. and Baues, C. (2018). Abscopal effects in metastasized cancer patients treated with PD-1 inhibition and radiation therapy. Strahlenther. Onkol., 194. S. S200 - 1. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X
Weiss, J., Knuver, J., Schlaak, M., Kreuzer, K., Hallek, M. and Mauch, C. (2016). Minimal-invasive tumor monitoring of BRAF V600E positive tumors in cell-free plasma DNA. J. Dtsch. Dermatol. Ges., 14. S. 11 - 13. HOBOKEN: WILEY-BLACKWELL. ISSN 1610-0387